Viramed - Model IgG and IgA - Bordetella Pertussis for the Quantitative Detection
The Bordetella pertussis ViraChip IgG and IgA are protein microarrays for the quantitative detection of IgG and IgA antibodies against Bordetella species antigens in human serum. As a miniaturized immunoblots based on an enzyme immunoassay, the Bordetella pertussis ViraChip® IgG and IgA use purified specific native antigens: Filamentous Hemagglutinin (FHA) and Pertussis Toxin (PT). To quantify antigen titers via the ViraChip® software, the FHA and the PT antigen triplets are applied in two, respectively in three different concentrations, intended to differentiate between a recent contact with Bordetella pertussis and a past infection. The Bordetella pertussis ViraChip® IgG and IgA Test Kits are composed of 96 single breakable wells each placed in a standard microtiter plate. The test procedure can be performed with common ELISA processors. The ViraChip® Software controls the entire process including the analysis of the test results.
PT and FHA antibody quantitation in international units
Transmission of quantitative data directly to the LIS
Reactivities of PT and FHA calibrated with WHO standards
Indication of a recent exposure
IgG: anti-PT ≥ 100 IU/ml or anti-FHA ≥ 90 IU/ml
IgA: anti-PT ≥ 12 IU/ml or anti-FHA ≥ 50 IU/ml
The PT antigen
Reliable detection of antibodies against Bordetella pertussis
The FHA antigen
Reliable detection of antibodies against Bordetella species
All relevant controls are integrated within the Bordetella pertussis ViraChip® IgG, IgA
Safe interpretation according to guidelines and recommendations in the laboratory routine
Fully automated procedure on ELISA processors
Automated evaluation with the ViraChip® Software